Literature DB >> 366426

Experimental mycosis in immunosuppressed rabbits. II. Acute and chronic aspergillosis.

J W Rippon, D N Anderson.   

Abstract

The influence of immunosuppression on the course of experimental aspergillosis was investigated. Rabbits (2.2--2.5 kg) were divided into four groups. Group one received no drugs and was given 10(6) spores intravenously (IV) or intratracheally (IT) on two occasions one week apart. Weight gain or loss, appearance or disappearance of aspergillus antigen and/or antibody, and detection of aspergillosis at autopsy were followed. Group 2 received weekly injections of cyclophosphamide (70 mg/kg) starting two weeks prior and throughout the experiment. Animals in group three received either 1.14 or 2.25 mg/kg/day methyl prednisolone and group four received 2.28 mg/kg/day methyl prednisolone and 70 mg/kg/week cyclophosphamide. In group one, serum antigen levels were detected within a week of infection followed by antibody (I.D.) levels for three months. All animals grew normally and no infection was detected at autopsy. In group 2, animals survived one but not two challenges and had Ag but no Ab. In group 3, animals survived two challenges at the lower drug level but not the higher. All animals in group 4 succumbed to one challenge.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 366426     DOI: 10.1007/bf00440968

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  14 in total

1.  Serological studies on Aspergillus fumigatus.

Authors:  M FUKUI; J YASUDA
Journal:  Mycopathol Mycol Appl       Date:  1961-02-20

2.  The diagnosis of aspergillosis by passive hemagglutination.

Authors:  J M Senet; C Brisset
Journal:  Biomedicine       Date:  1973-08-10

3.  Bronchial brushing in the diagnosis of pulmonary disease in patients at risk for opportunistic infection.

Authors:  R Finley; E Kieff; S Thomsen; J Fennessy; M Beem; S Lerner; J Morello
Journal:  Am Rev Respir Dis       Date:  1974-03

4.  Mechanism of production of candida lesions in rabbits.

Authors:  V N Damordaran; S C Chakravarty
Journal:  J Med Microbiol       Date:  1973-08       Impact factor: 2.472

5.  Aspergillosis: comparative virulence, metabolic rate, growth rate and ubiquinone content of soil and human isolates of Aspergillus terreus.

Authors:  J W Rippon; D N Anderson; M S Hoo
Journal:  Sabouraudia       Date:  1974-07

Review 6.  The current status of serologic, immunologic and skin tests in the diagnosis of pulmonary mycoses. Report of the Committee on Fungus Diseases and Subcommittee on Criteria for Clinical Diagnosis--American College of Chest Physicians.

Authors: 
Journal:  Chest       Date:  1973-02       Impact factor: 9.410

7.  Experimental pathology of Aspergillus terreus-flavipes group species.

Authors:  R S Pore; H W Larsh
Journal:  Sabouraudia       Date:  1968-02

8.  Invasive aspergillosis. Absence of detectable antibody response.

Authors:  R C Young; J E Bennett
Journal:  Am Rev Respir Dis       Date:  1971-11

9.  Nature of the skin-reactive principle in culture filtrates prepared from Paracoccidioides brasiliensis.

Authors:  A Restrepo-Moreno; J D Schneidau
Journal:  J Bacteriol       Date:  1967-06       Impact factor: 3.490

10.  Use of the immunodiffusion test in the serodiagnosis of aspergillosis.

Authors:  R M Coleman; L Kaufman
Journal:  Appl Microbiol       Date:  1972-02
View more
  2 in total

Review 1.  A guide to the recent literature on aspergillosis as caused by Aspergillus fumigatus, a fungus frequently found in self-heating organic matter.

Authors:  P B Marsh; P D Millner; J M Kla
Journal:  Mycopathologia       Date:  1979-11-30       Impact factor: 2.574

2.  Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes.

Authors:  A Schaffner; H Douglas; A Braude
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.